Ask AI
ProCE Banner Activity

BRUIN: Final Update From Phase I/II Trial of Pirtobrutinib for CLL/SLL Previously Treated With a Covalent BTKi

Conference Coverage
Slideset

With more than 5 years of follow-up, final results from the phase I/II BRUIN trial of pirtobrutinib in patients with CLL/SLL previously treated with a covalent BTK inhibitor demonstrated continued favorable efficacy, with an ORR of 81.6%, and manageable toxicity, with no new safety signals.

Released: December 19, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals caring for patients with relapsed/refractory CLL globally.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and enhance outcomes for patients with relapsed/refractory CLL

  • Appraise the potential clinical implications of new data on novel targeted and cellular therapies for treatment selection and sequencing in patients with relapsed/refractory CLL

  • Support effective shared decision-making through patient education and resources on the potential clinical implications of recently presented data for relapsed/refractory CLL